ReviewBiomedicines2021
Treatment of Dyslipidaemia in Children.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Familial hypercholesterolemia - treatment update in children, systematic review.Pediatric endocrinology, diabetes, and metabolism · 2022Pooled it
- Cardiometabolic outcome of MyBFF@school intervention program among secondary schoolchildren: a cluster randomized controlled trial.BMC public health · 2026Trial
- Podocytopathies.Nature reviews. Disease primers · 2025Review
- Article
- Pediatric Familial Hypercholesterolemia: Targeting Intestinal Absorption and Other Therapeutic Strategies.Nutrients · 2025Review
- Clinical Management of Dyslipidemia in Infants and Toddlers.Current atherosclerosis reports · 2025Review
- What Shapes Quality of Life in Youth? A Multidimensional Approach from Lifestyle to Residential Context-Cor-School Study.Healthcare (Basel, Switzerland) · 2025Article
- Post-marketing quality assessment of some brands of rosuvastatin tablets available in Jos, North-Central Nigeria.BMC chemistry · 2025Article
- Oxidative stress and pediatric diabetic cardiovascular complications: emerging research and clinical applications.American journal of physiology. Heart and circulatory physiology · 2025Review
- Formulation and Characterization ofInternational journal of nanomedicine · 2025Article
- Uncovering the inflammatory profile of obese children: examining the link between body mass index for age and insulin resistance in the Gaza Strip.Frontiers in pediatrics · 2025Article
- Review
- Emerging therapies for refractory hypercholesterolemia: a narrative review.Future cardiology · 2024Review
- Pediatric hyperlipidemia.Indian heart journal · 2024Review
- Statins-Beyond Their Use in Hypercholesterolemia: Focus on the Pediatric Population.Children (Basel, Switzerland) · 2024Review
- General and central obesity prevalence in young adult: a study based on the Rafsanjan youth cohort study.Scientific reports · 2023Article
- Statins in Children with Neurofibromatosis Type 1: A Systematic Review of Randomized Controlled Trials.Children (Basel, Switzerland) · 2023Review
- Hyperlipidemia and Cardiovascular Risk in Children and Adolescents.Biomedicines · 2023Review
- Statins in Children, an Update.International journal of molecular sciences · 2023Review
- Dyslipidemia in youth: Epidemiology, pathophysiology, screening, management, and treatment: A review of the literature.Journal of family medicine and primary care · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood dyslipidaemia is one of the main traditional cardiovascular risk factors that initiate and exacerbate the atherosclerotic process. Healthcare providers may play a key role in the management of children with lipid abnormalities; however, they have to properly evaluate the normal lipid values and know the available treatment options in children and adolescents. Current guidelines recommend healthy behaviours as the first-line treatment for childhood dyslipidaemia. The therapeutic lifestyle changes should focus on dietary modifications, daily physical activity, reduction in body weight and tobacco smoking cessation. Parents play a key role in promoting their children's healthy habits. In children with more severe forms of lipid abnormalities and in those who do not benefit from healthy behaviours, pharmacological therapy should be considered. Safe and effective medications are already available for children and adolescents. Statins represent the first-line pharmacological option, while ezetimibe and bile acid sequestrants are usually used as second-line drugs. Despite their limited use in children, other lipid-lowering agents (already approved for adults) are currently available or under study for certain categories of paediatric patients (e.g., familial hypercholesterolemia). Further studies are needed to evaluate the long-term efficacy, safety and tolerability of novel lipid-lowering drugs, especially in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.